RT Journal Article
SR Electronic
T1 Brain Injury in COVID-19 is Associated with Autoinflammation and Autoimmunity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.03.21266112
DO 10.1101/2021.12.03.21266112
A1 EJ Needham
A1 AL Ren
A1 RJ Digby
A1 JG Outtrim
A1 DA Chatfield
A1 AE Manktelow
A1 VFJ Newcombe
A1 R Doffinger
A1 G Barcenas-Morales
A1 C Fonseca
A1 MJ Taussig
A1 RM Burnstein
A1 C Dunai
A1 N Sithole
A1 NJ Ashton
A1 H Zetterberg
A1 M Gisslen
A1 A Edén
A1 E Marklund
A1 MJ Griffiths
A1 J Cavanagh
A1 G Breen
A1 SR Irani
A1 A Elmer
A1 N Kingston
A1 JR Bradley
A1 LS Taams
A1 BD Michael
A1 ET Bullmore
A1 KGC Smith
A1 PA Lyons
A1 AJC Coles
A1 DK Menon
A1 the Cambridge NeuroCOVID Group
A1 the NIHR COVID-19 BioResource
A1 Cambridge NIHR Clinical Research Facility
YR 2021
UL http://medrxiv.org/content/early/2021/12/05/2021.12.03.21266112.abstract
AB COVID-19 has been associated with many neurological complications including stroke, delirium and encephalitis. Furthermore, many individuals experience a protracted post-viral syndrome which is dominated by neuropsychiatric symptoms, and is seemingly unrelated to COVID-19 severity. The true frequency and underlying mechanisms of neurological injury are unknown, but exaggerated host inflammatory responses appear to be a key driver of severe COVID-19 more broadly.We sought to investigate the dynamics of, and relationship between, serum markers of brain injury (neurofilament light [NfL], Glial Fibrillary Acidic Protein [GFAP] and total Tau) and markers of dysregulated host response including measures of autoinflammation (proinflammatory cytokines) and autoimmunity. Brain injury biomarkers were measured using the Quanterix Simoa HDx platform, cytokine profiling by Luminex (R&D) and autoantibodies by a custom protein microarray.During hospitalisation, patients with COVID-19 demonstrated elevations of NfL and GFAP in a severity-dependant manner, and there was evidence of ongoing active brain injury at follow-up 4 months later. Raised NfL and GFAP were associated with both elevations of pro-inflammatory cytokines and the presence of autoantibodies; autoantibodies were commonly seen against lung surfactant proteins as well as brain proteins such as myelin associated glycoprotein, but reactivity was seen to a large number of different antigens.Furthermore, a distinct process characterised by elevation of serum total Tau was seen in patients at follow-up, which appeared to be independent of initial disease severity and was not associated with dysregulated immune responses in the same manner as NfL and GFAP.Competing Interest StatementHZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. MG has received research grants from Gilead Sciences and Janssen-Cilag and honoraria as speaker and/or scientific advisor from Amgen, Biogen, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV, Janssen-Cilag, MSD, Novocure, and Novo Nordic SRI is a coapplicant and receives royalties on patent application WO/210/046716 (U.K. patent no., PCT/GB2009/051441) entitled Neurological Autoimmune Disorders (licensed for the development of assays for LGI1 and other VGKC-complex antibodies) and Diagnostic Strategy to improve specificity of CASPR2 antibody detection. (PCT/G82019 /051257). SRI has received honoraria and/or research support from UCB, Immunovant, MedImmun, Roche, Cerebral therapeutics, CSL Behring, ONO Pharma and ADC therapeutics. VFJN holds a grant from Roche Pharmaceuticals on proteomic biomarkers in traumatic brain injury. EB serves on the scientific advisory board of Sosei Hepatares and as a consultant for GSK. MT is the founder and CEO of Cambridge Protein Arrays Ltd. DKM reports grants, personal fees, and nonfinancial support from GlaxoSmithKline Ltd.; grants, personal fees, and other from NeuroTrauma Sciences; grants and personal fees from Integra Life Sciences; personal fees from Pfizer Ltd.; grants and personal fees from Lantmannen AB; from Calico Ltd.; personal fees from Pressura Neuro Ltd.; and others from Cortirio Ltd., outside the submitted work. AJC received honoraria and travel expenses from Genzyme (a Sanofi company) until September 2017. VFJN reports personal fees from Neurodiem, outside the submitted work. Funding StatementEN, DKM and AC are supported by Brain Research UK. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimers Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen for Gamla Tjanarinnor, Hjarnfonden, Sweden (#FO2019-0228), the European Unions Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. MG is supported by the Swedish State Support for Clinical Research ( ALFGBG-717531) and by grants from the SciLifeLab National COVID-19 Research Program, financed by the Knut and Alice Wallenberg Foundation (KAW 2020.0182 and 2020.0241). GB is supported by a sabbatical grant from PASPA-DGAPA-UNAM, Mexico. SRI is supported by a Wellcome Trust Fellowship [104079/Z/14/Z], a Medical Research Council Fellowship [MR/V007173/1], BMA Research Grants- Vera Down grant (2013) and Margaret Temple (2017), Epilepsy Research UK (P1201), the Fulbright UK-US commission (MS-Society research award) and by the NIHR Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. VFJN is an Academy of Medical Sciences / The Health Foundation Clinician Scientist. EB is supported by an NIHR Senior Investigator award DKM is supported by an NIHR Senior Investigator Award and European Union 7th Framework program We would like to thank Addenbrookes Charitable Trust and the NIHR Cambridge Biomedical Research Centre for their funding, and the NIHR Cambridge Clinical Research Facility outreach team for enrollment of patients. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Swedish Ethical Review Authority (2020 01771) and the East of England Cambridge Central Research Ethics Committee (17/EE/0025); via the Cambridge Biomedical Research Centre). Healthy controls were recruited through the Cambridge Biomedical Research Centre (prior to the COVID 19 pandemic) and all provided written consent (approved by East of England Cambridge Central Research Ethics Committee 17/EE/0025). Data from a small positive control group consisting of patients with acute traumatic brain injury were included as a reference for the magnitude of brain injury biomarker elevations (approved by East of England Cambridge Central Research Ethics Committee REC 97/290).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon request to the authors